Protaryx Medical Welcomes David Mester as New CEO to Spearhead Advancements in Transseptal Access Technology
Retrieved on:
Tuesday, September 12, 2023
Health, Surgery, Cardiology, Medical Devices, Area studies, Heart, Boyd, AAMI, Latham, University, Louisiana State University, ISO, USB On-The-Go, MBA, University of North Carolina at Charlotte, Science, Acquisition, Latham & Watkins, Growth, FDA, Association for the Advancement of Medical Instrumentation, Management, Pharmaceutical industry, Silicon, Mester
Protaryx Medical, a pioneer in medical device innovation, today announced the appointment of David Mester, MBA as its new chief executive officer (CEO).
Key Points:
- Protaryx Medical, a pioneer in medical device innovation, today announced the appointment of David Mester, MBA as its new chief executive officer (CEO).
- Protaryx Medical is known for its Protaryx Transseptal Access Device, a cutting-edge technology for transseptal procedures that provides streamlined access to the left side of the heart through the fossa ovalis.
- What sets the Protaryx device apart is its unique integration of access and transseptal crossing functions into a single device that can be used independently or integrated with another therapy device.
- Prior to joining Protaryx Medical, Mester held pivotal senior business and technical leadership roles at Sequoia Medical, Xeltis, Gore Medical, CarboMedics, and ViVitro Labs.